Zoledronska kiselina
Klinički podaci | |||
---|---|---|---|
Robne marke | Aclasta, Reclast, Zometa, Zometa Concentrate | ||
AHFS/Drugs.com | acid.html Monografija | ||
Identifikatori | |||
CAS broj | 118072-93-8 | ||
ATC kod | M05BA08 | ||
PubChem[1][2] | 68740 | ||
DrugBank | DB00399 | ||
ChemSpider[3] | 61986 | ||
ChEMBL[4] | CHEMBL924 Y | ||
Hemijski podaci | |||
Formula | C5H10N2O7P2 | ||
Mol. masa | 272,090 | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakokinetički podaci | |||
Poluvreme eliminacije | 146 h | ||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | |||
Način primene | Intravenozno |
Zoledronska kiselina je organsko jedinjenje, koje sadrži 5 atoma ugljenika i ima molekulsku masu od 272,090 Da.[5][6][7][8][9]
Osobine
Osobina | Vrednost |
---|---|
Broj akceptora vodonika | 8 |
Broj donora vodonika | 5 |
Broj rotacionih veza | 4 |
Particioni koeficijent[10] (ALogP) | -1,2 |
Rastvorljivost[11] (logS, log(mol/L)) | 1,8 |
Polarna površina[12] (PSA, Å2) | 172,7 |
Reference
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑ Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S: Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med. 2007 Sep 26;. PMID 17878149
- ↑ Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002 Feb 28;346(9):653-61. PMID 11870242
- ↑ Durie BG, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102. PMID 16000365
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682. edit
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412. edit
- ↑ Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A 102: 3762-3772. DOI:10.1021/jp980230o.
- ↑ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488-1493. DOI:10.1021/ci000392t. PMID 11749573. edit
- ↑ Ertl P., Rohde B., Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714-3717. DOI:10.1021/jm000942e. PMID 11020286. edit
Literatura
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
Spoljašnje veze
Portal Medicina | |
Portal Hemija |
Zoledronska kiselina na Wikimedijinoj ostavi
- Zoledronic acid
- p
- r
- u
Lekovi za tretman bolesti kostiju (M05)
Azotni (Alendronska kiselina, ibandronska kiselina, inkadronska kiselina, pamidronska kiselina, risedronska kiselina, zoledronska kiselina)
bez-azotni (Etidronska kiselina, klodronska kiselina, tiludronska kiselina)
bez-azotni (Etidronska kiselina, klodronska kiselina, tiludronska kiselina)
Inhibitor resorpcije (Ipriflavon) • Aluminijum hlorohidrat • Koštani agens dualnog dejstva (Stroncijum ranelat) • RANKL inhibitor (Denosumab) • Katepsin K inhibitor (Odanakatib)